Susan G. Komen Invests $15.4M in 2026, Driving 44% Drop in U.S. Breast Cancer Deaths Since 1989
Event summary
- Susan G. Komen released its 2026 Annual Impact Report, highlighting $15.4M in research investments, 72% of which went to metastatic breast cancer.
- The organization has driven a 44% decline in breast cancer deaths in the U.S. since 1989 through $1.1B in research and $2.7B in patient support.
- Komen advanced 42 policies across 34 states, with 12 signed into law, focusing on screening, diagnostic imaging, genetic testing, and treatment.
- The organization served over 21,000 people through its Patient Care Center and provided $5.4M in financial assistance to patients and families.
- A social impact documentary, 'Conquering Breast Cancer,' premiered at the World Cancer Congress in Hong Kong on September 25, 2026.
The big picture
Susan G. Komen's 2026 investments underscore its role as a leader in breast cancer research and advocacy, with a strategic focus on reducing disparities and advancing precision medicine. The organization's comprehensive approach—spanning research, policy, and patient support—positions it to drive further declines in breast cancer mortality, particularly among underserved populations. With $1.1B invested in research and $2.7B in patient support since its founding, Komen's impact is evident in the 44% drop in U.S. breast cancer deaths since 1989.
What we're watching
- Research Focus
- Whether Komen's emphasis on metastatic breast cancer and precision medicine will accelerate therapeutic breakthroughs.
- Policy Impact
- The pace at which state-level policy advancements will improve access to high-quality care and reduce disparities.
- Health Equity
- How sustained investments in disparities research will affect mortality rates among Black and Hispanic/Latina women.
Related topics
